Torrent Pharmaceuticals

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by ICRA.
• ResultsMixedIn the Sep 2026 quarter, sales rose 51% and profit fell 9.6% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 61%, down from 68% in Sep 2025.
• ValuationExpensive vs its pastThe share trades at 78.5 times its yearly earnings (P/E), pricier than 95% of the time in the last 5 years. Its usual P/E is about 26.

Torrent Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)78.5 against a typical 33.2: pricier than most peers (1st = cheapest).183rd of 220
• Sales growth+50.8% against a typical +15.6% from a year earlier.30th of 197
• Profit growth−9.6% against a typical +18.9% from a year earlier.108th of 160
• Share price, 3 months−5.2% against a typical −2%.120th of 200
• Size₹ 1,70,474.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).3rd of 199

Exchange filings and their impact on the company.

• 23 Oct 2026Outcome of Board MeetingHigh impactPositivePrice +0.6% on 26 Oct
  JB merger drives 40%+ revenue jump with margins up but PAT flat and EPS diluted by debt and new shares.

  Torrent Pharma reported Q2 FY27 revenue of Rs 4,979 crores, up 51% year-on-year, and operating EBITDA of Rs 1,666 crores, up 54% with 33.5% margin, while net profit fell 10% to Rs 534 crores due to higher interest and depreciation from the JB Chemicals acquisition. Base business grew 18% led by India up 20% and Brazil up 38% and US up 24%, while JB India grew 7% with a transient merger impact. The JB merger completed on 8 July 2026 with 4.19 crore new shares issued, sharply scaling revenue but diluting EPS in the near term.

  Full analysisFiling
• 16 Oct 2026Change in ManagementLow impactNeutralPrice 0% on 19 Oct
  Torrent Pharma's Executive Director Amal Kelshikar resigned effective 16 Oct 2026.

  Torrent Pharmaceuticals informed the exchanges that Amal Kelshikar, Executive Director designated as Senior Management Personnel, has resigned effective close of business on 16th October 2026. No reason, successor, or financial impact was disclosed in the filing. For a company of Torrent's scale, the exit is not expected to materially change operations over the next 12 months.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Samir Mehta

Executive Chairman of the Board

Sudhir Menon

Chief Financial Officer, Executive Director - Finance

Chintan M. Trivedi

Chief Compliance Officer, Company Secretary

Aman Samir Mehta

Managing Director, Whole-Time Director